Also available on ScienceDirect
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Gary Lichtenstein
985 SURREPTITIOUS CORTICOSTEROID USE IDENTIFIED BY FORMAL PHARMACOKINETIC AND HPA-AXIS TESTING IN A PHASE 3 ULCERATIVE COLITIS CLINICAL TRIAL
Also available on ScienceDirect
Mo1596 REAL-WORLD COMPARATIVE EFFECTIVENESS OF GUSELKUMAB VERSUS USTEKINUMAB IN ULCERATIVE COLITIS: A PROPENSITY MATCHED ANALYSIS
Also available on ScienceDirect
Su1666 ASSOCIATION OF ENDOSCOPIC, HISTOLOGIC, AND COMPOSITE OUTCOMES WITH LONG-TERM GUSELKUMAB EFFICACY IN ULCERATIVE COLITIS: 2-YEAR RESULTS FROM THE QUASAR LONGTERM EXTENSION
Also available on ScienceDirect
Ulcerative Colitis
Dr. Lichtenstein is a gastroenterologist specializing in inflammatory bowel disease, serving as the Director of the Inflammatory Bowel Disease Center at the University of Pennsylvania. With over 250 peer-reviewed publications, he has made significant contributions to medical literature, shedding light on the treatment and understanding of ulcerative colitis and Crohn's disease.
Ulcerative Colitis
Introduction Although patients with inflammatory bowel disease (IBD) may have genetic predispositions to develop such diseases, this alone does not appear to be sufficient for the onset of inflammation. An important role for environmental factors in disease onset is suggested by higher incidence rates in industrialized countries as well as rising incidence rates in less developing countries.
Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis-what can we learn?
INVITED EDITORIAL Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis—what can we learn? Gary R. Lichtenstein Corresponding Author E-mail address: Gary.Lichtenstein@uphs.upenn.edu https://orcid.org/0000-0002-1913-2957 Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania Search for more papers by this author PDF PDF Share Abstract Linked Content This article is linked to Olaisen et al and Olaisen and Fossmark papers.
Switching Between Reference and Biosimilar Infliximab
Table 1. Biosimilar TNF blockers currently approved by the US FDA 8, 9 Reference product Biosimilar Synonyms Date of FDA approval Infliximab Infliximab-dyyb CT-P13 5 April 2016 Infliximab-abda SB2 21 April 2017 Infliximab-qbtx PF-06438179, GP1111 13 December 2017 Adalimumab Adalimumab-atto ABP 501 23 September 2016 Adalimumab-adbm BI 695501 25 August 2017 Etanercept Etanercept-szzs GP2015 30 August 2016 FDA, Food and Drug Administration; TNF, tumour-necrosis factor. Table 2.
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
Summary Background Biosimilar versions of widely prescribed drugs, including the tumour‐necrosis factor antagonist infliximab, are becoming increasingly available. As biosimilars are not identical copies of reference products, evidence may be required to demonstrate that switching between a reference biologic and biosimilars is safe and efficacious.
New ACG Crohn’s guideline reflects ‘cross-fertilization’ of knowledge
Disclosures : Lichtenstein reports financial relationships with AbbVie, Actavis, Alaven, CellCeutrix, Celgene, Ferring, Gilead, Hospira, Janssen, Orthobiotech, Ironwood, Luitpold/American Regent, Merck, Pfizer, Prometheus Laboratories, Romark, Salix Pharmaceuticals/Valeant, Santarus/Receptos/Celgene, Shire Pharmaceuticals, Takeda, UCB. Please see the full guideline for a list of all other co-authors’ relevant financial disclosures.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Gary
Contact Gary, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack